Tecentriq: Ph I data

Data from 112 evaluable patients with metastatic triple-negative breast cancer (TNBC) in an expansion cohort of an open-label, international Phase I trial showed that 15 or 20 mg/kg IV Tecentriq every 3 weeks led to an ORR of 10%, including 3 complete responses (CRs) and 8 partial responses (PRs), plus 15 cases of stable disease. The clinical benefit rate (CBR) was 23% and the median duration of response was 21 months. Additionally, atezolizumab led to 1-, 2- and 3-year OS rates of 41%, 22% and 22%, respectively. The median OS in responders was not reached and the median OS in non-responders who lived for ≥6 weeks was 9 months.

In 19 evaluable patients who received Tecentriq as first-line therapy, the ORR was 26%, including 2 CRs and 3 PRs, plus 3 cases of stable disease. The CBR was 42% and the median duration of response was 21 months. OS rates were 63% at 1 year, 47% at 2 years and not evaluable at 3 years. In 93 evaluable patients who received ≥2 lines of therapy prior to Tecentriq, the ORR was 7%, including 1 CR and 5 PRs, plus 12 cases of stable disease. The CBR was 19% and the median duration of response was not evaluable. OS rates were 37% at 1 year, 18% at 2 years and 18% at 3 years. Data were presented at the American Association for Cancer Research meeting in Washington, D.C...